| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 20.02. | FDA starts review of Regeneron's drug for rare disease FOP | ||
| 20.02. | Grail's multi-cancer test fluffs its lines in UK trial | ||
| 20.02. | UK firm steps in to ease medicine supply crisis in NHS | ||
| 20.02. | Texas sues Sanofi, claiming kickbacks to doctors | ||
| 20.02. | Ex-Novartis CMO John Tsai joins Daiichi Sankyo | ||
| 19.02. | Hims & Hers buys Australian digital health firm for $1.15bn | ||
| 19.02. | Makary says FDA will "end two-trial dogma" for approvals | ||
| 19.02. | NICE backs changes to NHS' diabetes care pathway | ||
| 19.02. | NIH Director Bhattacharya will temporarily run CDC | ||
| 19.02. | MSD and Mayo Clinic team up on AI drug discovery | ||
| 18.02. | FDA relents and will review Moderna's flu shot | ||
| 18.02. | FDA changes course and agrees to review Moderna's flu shot | ||
| 18.02. | FDA starts review of BMS's 'celmod' for multiple myeloma | ||
| 18.02. | Number of UK biotech companies rising, says report | ||
| 18.02. | Novartis' oral BTK drug moves the needle in CINDU | ||
| 18.02. | NICE backs first disease-modifying drug for ARG1 deficiency | ||
| 17.02. | NHS study will pick apart mental illness with data science | ||
| 17.02. | Compass points to strong psilocybin data in depression | ||
| 17.02. | EU approval for new asthma drug Exdensur lifts GSK | ||
| 17.02. | Mark Dawson named head of Roche's pRED unit | ||
| 17.02. | Helus' psychedelic drug DMT 'could help treat depression' | ||
| 16.02. | UK seeks views on indefinite CE marks for medical devices | ||
| 16.02. | Roche trial offers hope to patients with rare kidney disease | ||
| 16.02. | AI in drug development news round-up | ||
| 16.02. | FDA turns down 'national priority' drug from Disc Medicine |